A Multi-centre, Prospective, Single-arm, Non-interventional Study Describing the Use of the Dose Check App in People Living With Type 2 Diabetes Mellitus and Treated With IDegLira in a Real-world Setting in Italy
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 30 Sep 2024 Planned End Date changed from 2 Sep 2025 to 2 Mar 2026.
- 30 Sep 2024 Planned initiation date changed from 7 May 2024 to 7 Nov 2024.
- 30 Sep 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.